Drugs / RPH-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03659305 | Jul 2018 → Jan 2019 | — | R-Pharm | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-06-17 | R-Pharm | Results «Р-Фарм» продемонстрировал результаты исследования препарата RPH-001 в ходе медицинского форума r-pharm.com ↗
Он рассказал собравшимся, что, согласно полученным данным, подтверждена биоэквивалентность препарата RPH-001 и Авастина. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-06-17 | R-Pharm | «Р-Фарм» продемонстрировал результаты исследования препарата RPH-001 в ходе медицинского форума r-pharm.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPH-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03659305 ↗ |
| Action | Inhibit | “Humanized recombinant monoclonal anti-VEGF antibody.” NCT03659305 ↗ |
| Modality | Monoclonal antibody | “Humanized recombinant monoclonal anti-VEGF antibody.” NCT03659305 ↗ |
| Route | Intravenous | “5 mg/kg single intravenous infusion (for no less than 90 minutes)” NCT03659305 ↗ |